Sydney Health Partners

ACTA Trial of the Year V3

ACTA Trial of the Year
A clinical trial which took more than a decade to complete but produced compelling evidence for a change in the treatment of premature babies has been named the Australian Clinical Trials Alliance (ACTA) Trial of the Year.
More >
Polypharmacy in the elderly

Polypharmacy in the elderly
For many elderly Australians, a regimen of several prescription drugs is a daily fact of life.Over time, often beginning in middle age, health consumers can accumulate prescriptions to the point where they are using more medications than is medically necessary.
More >
Sydney Health Partners Symposium

Sydney Health Partners Symposium
Watch the highlights from our Symposium, Research Translation in a Complex Health System.
More >

NOVEL LOW-COST GENE TEST COULD IMPROVE TREATMENT OF BREAST CANCER

Dr Dinny Graham
Dr Dinny Graham

A low-cost test to more accurately predict which breast cancers are at higher risk of relapse and thus inform better treatment decisions, is being pioneered by researchers and clinicians in the Sydney Health Partners network.

The PROSPER-2 genomic test could become a quick, low-cost and hospital-delivered alternative to commercially available genomic testing of breast cancer, which is often unaffordable for patients.

A project to test the accuracy of PROSPER-2 compared to other prognostic tools has received a grant from Sydney Health Partners, using money from the Medical Research Future Fund.

Lead investigator Dr Dinny Graham, from Sydney Health Partners member, the Westmead Institute for Medical Research, said that by measuring the molecular expression of a small handful of genes, the test predicts which tumours are more aggressive and less likely to respond to conventional treatments.

“Current diagnostic methods for predicting whether a patient is likely to respond well to standard treatments return an ambiguous result in up to one third of cases and the ideal treatment path for these patients is not 100% clear,” said Dr Graham.

“Despite multiple studies now demonstrating the advantages of adding multi-gene tests to traditional prognostic tools when evaluating breast cancer cases, the uptake in Australia has been limited,” said Dr Graham.

“Almost no-one gets these tests because they cost several thousand dollars, there is no Medicare subsidy and for some tests the tumour sample has to be sent interstate or overseas to be tested.”

“We believe the PROSPER-2 test will cost less than $100 dollars, can be done in a clinical setting and will be at least, if not more, accurate than the current tests.”

For the majority of women diagnosed with breast cancer, the standard treatment is with endocrine agents, which are highly effective, generally well tolerated and lack the damaging side effects of cytotoxic chemotherapies.

In a proportion of cases, however, clinical pathology evaluation of the cancer tissue suggests that the patient is at an elevated risk of relapsing after the tumour is removed. These patients usually receive chemotherapy in an effort to reduce that risk. Current methods to identify these patients are not perfect, meaning that some patients may receive unnecessary chemotherapy.

Dr Graham’s team of researchers identified the gene signature that would provide the best prediction of a breast cancer’s relapse risk by analysing bioinformatics data gathered during a previous, much more extensive, genetic testing project.

They will now use the novel technique to test a large bank of breast cancer tissue gathered from patients over many years.

The project is a cross-disciplinary investigation involving genomic research, clinical pathology, surgery and oncology.

“The use of PROSPER-2 testing for these equivocal cases will add confidence to treatment decisions and provide firm data on which to make a recommendation to patients about whether to stay on endocrine treatment or escalate to chemotherapy,” said Dr Graham.

“The result should be improved treatment outcomes, longer patient survival, improved productivity and the economic benefits to the public health system that will flow as a result from those gains.”

“This is potentially highly translational and we hope that what we are finding will bring low cost molecular testing into clinical practice for the treatment of breast cancer patients in the Australian public health environment.”

PROSPER-2 was one of 13 competitive grants awarded by SHP in January this year, supporting projects across the Sydney, Northern and Western Local Health Districts.
Sydney Health Partners is a Commonwealth Government-accredited Advanced Heath Research and Translation Centre, tasked with delivering the benefits of research and innovation faster and more consistently.

To see the full list of 2018 SHP-funded projects, please click here


Sydney Health Partners

Opinion Piece: How $10 million in medical research funding can transform the health system, and transform lives
Sydney Health Partners’ Chief Executive Professor Garry Jennings AO on how funding from the Medical Research Future Fund can deliver new solutions to the health system, and improve the health and wellbeing of the community.
More >
Sydney Health Partners

Sydney Health Partners welcomes Federal Government's announcement of funding for translational research
We welcome the Federal Government's announcement of $10 million in funding from the Medical Research Futures Fund to support AHRTCs.
More >
Sydney Health Partners

Opinion Piece: We all have a right to medical care. But with that comes responsibilities
Professor David Celermajer, of Sydney Health Partners' members The University of Sydney and Sydney Local Health District's RPA Hospital, talks about the importance of organ donation in his recent opinion piece.
More >
Sydney Health Partners

Call for abstracts: 6th Annual NHMRC Symposium on Research Translation
The call for abstracts is now open for this year's Symposium, which will be co-hosted with the Lowitja Institute in Brisbane from 14-15 November. The theme is "The Butterfly Effect: Translating knowledge into Action for Positive Change", with a focus on the action needed to improve the health and wellbeing of Australia's First Peoples through effective translation of health, wellbeing and medical research into policy and practice.
More >
Sydney Health Partners

Study finds one energy drink dangerous for some
A world-first study by cardiologists from Sydney Local Health District’s Royal Prince Alfred Hospital and the Centenary Institute, members of Sydney Health Partners, has found that having just one to two energy drinks could be life-threatening for some young people with no known history of heart disease.
More >
Sydney Health Partners

Breakthrough in treating asbestos related cancer
Researchers at the Asbestos Diseases Research Institute, part of Sydney Health Partners, have announced one of the most significant breakthroughs in asbestos related cancer treatment in a decade. See the patient stories of those who have benefited on Channel 9's A Current Affair.
More >
Sydney Health Partners

Evaluation Report: Sydney Health Partners Annual Forum
Read the evaluation of our 2017 Annual Forum System.
More >

© 2018 Sydney Local Health District
Disclaimer | Privacy Statement | Accessibility
Page Last Updated: 31 May, 2018